NMN vs Nicotinamide Riboside: Comparing the Evidence

Two precursors, one question

NAD+ is a molecule every cell uses to make energy and carry out repairs. Its levels in tissues fall with age in animal studies. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are two "precursors", raw materials the body can turn into NAD+. People often ask which one is better. The honest answer from the research we could read is that no head-to-head human trial was found, and neither has shown clear health benefits in older adults. For the biology, see NAD+ biology and its decline with age.

What the two have in common

• Both raise NAD-related markers in people. A 2026 systematic review of 33 human intervention studies and 80 rodent studies found oral NR and NMN consistently raised NAD-related substances in blood or cells and were generally well tolerated over weeks to months. Effects on function, metabolism and blood vessels were mixed and often null. [1]
• Both lack clear clinical benefit so far. The same review called clinical effectiveness for anti-aging or wellness outcomes inconclusive. [1]
• Both are short-trial evidence. The human trials below last weeks to a few months and mostly enroll small groups.

Side by side

What the NMN trials show

• In a 10-week randomized placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese, NMN increased muscle insulin sensitivity. [2] A published comment asked whether baseline differences between groups could have affected the result; the authors replied that muscle insulin sensitivity was identical at baseline. [10]
• In a placebo-controlled trial in older men given 250 mg a day (a study amount), blood NAD+ rose, gait speed and left-hand grip improved only nominally, and body composition did not change significantly. [3]
• Pooled analyses are less encouraging. One meta-analysis of 12 studies and 513 people found NMN raised blood NAD but most clinically relevant outcomes did not differ from control, with some or high risk of bias in all 12 studies. The authors suggested benefits may be exaggerated in this field. [8] Another of eight trials found no significant benefit on glucose or lipids. [7]
• A 2026 meta-analysis found a small fall in diastolic blood pressure and called the finding preliminary. [11] A smaller 2025 meta-analysis of nine studies reported a gait-speed and liver-enzyme benefit. [12] Results across reviews disagree, which is why we label this mixed.
• Safety: a 2026 review of short NMN trials found no increase in overall, serious or system-specific adverse events. These were short trials, so long-term safety is unknown. [13]

What the NR trials show

• A six-week crossover trial found NR was well tolerated and raised NAD+ metabolism in healthy middle-aged and older adults. [4]
• In 12 older men, NR raised the muscle NAD+ metabolome, but muscle mitochondrial function did not change. [5]
• In 13 overweight or obese adults, NR caused no change in insulin sensitivity or mitochondrial function; small changes in fat-free mass and sleeping metabolic rate appeared. [6]

Muscle and strength: both together

A 2025 meta-analysis of randomized trials in adults with a mean age over 60 concluded current evidence does not support NMN or NR for preserving muscle mass and function. [9]

Rules and unknowns

• NMN in the United States. In a December 2, 2025 letter, FDA said it had determined NMN is not excluded from the dietary supplement definition. [14] This is a classification decision, not a finding that NMN works or has been reviewed for safety in the way a medicine is. Laws change and this is not legal advice.
• NR regulatory status: not verified this session.
• Possible risks being studied. A 2020 review warned of possible accumulation of toxic breakdown products, tumor promotion and promotion of cellular senescence when NAD+ is raised, and noted long-term human trials are still nascent. [15] These are open questions, not established harms.
• Conflicts of interest. One NMN trial lists patent-licensing income for an author [2]; another lists employees of a supplier company among authors [3].

How to judge claims

Ask whether a claim cites human outcomes or only NAD+ levels, whether the trial was randomized and how long it ran. See claim check: NAD+ boosters restore youthful energy and NAD+, NMN and nicotinamide riboside: what research shows.